Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)

A. Palumbo, S. Bringhen, A. Bertola, F. Cavallo, P. Falco, M. Massaia, B. Bruno, C. Rus, A. Barbui, T. Caravita, P. Musto, N. Pescota, F. Rossini, M. Vignetti, Mario Boccadoro

Research output: Contribution to journalArticlepeer-review


Several trials have shown the superior impact of high-dose melphalan (usually 200mg/m2, MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100mg/m2, MEL100) is also superior to the standard dose, but has not been clinically compared with MEL200. A total of 90 patients at diagnosis were treated with two MEL100 courses. Their clinical outcome was compared with that of a control group of 90 pair mates matched for serum β2-microglobulin levels and Durie and Salmon clinical stage. These patients were treated at diagnosis with two MEL200 courses. Patient characteristics were similar in both groups except that the median age of the MEL100 group was significantly higher (P

Original languageEnglish
Pages (from-to)133-138
Number of pages6
Issue number1
Publication statusPublished - Jan 2004


  • Dose-intensive
  • Melphalan
  • Myelomatransplantation

ASJC Scopus subject areas

  • Hematology
  • Cancer Research


Dive into the research topics of 'Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)'. Together they form a unique fingerprint.

Cite this